• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

Optimising daytime functioning through minimising flow limitations dur


  • Please log in to reply
17 replies to this topic

#1 Jacovis

  • Guest
  • 247 posts
  • 1

Posted 03 July 2008 - 12:31 PM


From my reading, this is Dr. Barry Krakow’s (author of ‘Sound Sleep, Sound Mind’) approach. More posts will follow from me but here is a page from his site. I have highlighted below what the focus of this thread will be on: excessive flow limitations (and not apneas/hypopneas) which can lead to Sleep fragmentation and Oxygen Fluctuations. I believe a lot of people (myself included) who have ‘brain fog’ and even depression do have flow limitations playing a prominent part in their sleep disordered breathing. These cause excessive Respiratory Related Respiratory Effort-Related Arousals (RERAs) during sleep even if Apneas and Hypopneas are only slightly elevated (or even normal). I believe for optimal daytime functioning, reducing the flow limitations/RERAs needs to be focused on rather just making sure a person’s Apnea-Hypopnea Index (AHI) is in the ‘normal’ range…


http://sleeptreatmen...nu-id-1110.html

Sleep Disordered Breathing

Sleep Disordered Breathing (SDB) is very complex breathing condition that destroys your slumber and endangers your health by two very prominent physiological processes:
• Sleep Fragmentation: SDB is so disruptive because it constantly interferes with your brain waves as you attempt to sleep. Instead of remaining in deeper, restorative stages of sleep for much of the night, SDB forces you into lighter sleep stages and in the most cases, it triggers hundreds of little awakenings during the night that literally rob you of sleep. In fact, if you sleep 8 hours and suffer from moderate to severe SDB, chances are high you are only getting 4 to 6 hours of solid sleep.
• Oxygen Fluctuations: SDB dramatically alters stabily of the oxygen your body receiveds into the body and transfers into your bloodstream. In a normal sleeper, oxygen levels are maintained in a surprisingly stable pattern. For, if the level were 94% (90 to 100% being the standard normal range), then this value could be maintained for minutes on end with minor or no fluctuations whatsoever. In most SDB cases, oxygen fluctuates all night long, often within a time span as short as a few seconds. In a 30 second interval (the standard interval we use in sleep studies), oxygen could start at 94%, drop to 91 in 10 seconds, go back up to 93$ in another 5 seconds, and then drop again to 89% in another 15 seconds. In more severe cases, these fluctuations deteriorate into what are known as desaturations, where the oxygen level drops frequently below 90% for 10, 20, 30 seconds or longer, before returning to the normal level above 90%. Sometimes oxygen drops even lower, particularly in REM sleep or when you sleep on your back.

These two components--sleep fragmentation and oxygen fluctuations/desaturations are the key to understanding the nature of SDB. Most importantly, it will help you understand why the term "obstuctive sleep Apnea" (OSA) is a misleading term. Sleep apnea literally refers to the process in which you stop breathing for anywhere from 10 seconds or longer, amazingly up to 60 seconds in unusually severe cases. As you would expect, sleep disruption and oxygen desaturations are quite severe following an apnea.
However, SDB comprises more than just a series of sleep apnea events. Indeed, you can suffer from extremely severe SDB without ever once stopping breathing. How could this be so? The answer is quite simple if you think about this analogy: a sleep apnea event is similar to a choking episode in which you stop breathing, say from inhaling a piece of food into your windpipe. This obstruction will surely produce intense fear if not outright panic in most people, bringing them to absolute alertness to solve the problem and solve it fast.

SDB can produce a response this severe when the airway closes down and all breathing stops, but to continue the analogy, how do you think you would react when you "choke a little?" I'm sure you guessed that it would still be very uncomfortable, and that's why SDB is often misunderstood and why the term sleep apnea is misleading. As you will learn, SDB can include a whole range of sleep breathing events in which you don't stop breathing, but your effort to bring in a full breath is compromised. Two events described below are usually more common than apneas in most patients with SDB:
• Hypopneas: In this event instead of a complete cessation of breathing, you lose about 50% of your normal breath, which unsurprisingly is more than sufficient to trigger sleep fragmentation and to cause your oxygen to fluctuate or desaturate.
Flow Limitation: In this event, the airway experiences resistance, which is diffiucult to quantity, but it might be reasonable to consider these events as a 10% reduction. Yet even this small reduction of breathing (a wee bit of choking) can still cause sleep fragmentation and oxygen fluctuations.
So, to reiterate, you will understand this condition much better and make better decisions about your healtcare choices by recognizing that when you suffer from SDB, it might be only apneas, only hypopneas or only flow limitations or as in most cases, some combination of all three event types. But even if you only suffer flow limitation events, they can cause severe sleep fragmentation and constant oxygen fluctuations that damage your sleep along with your mental and physical health.

#2 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 03 July 2008 - 12:46 PM

The studies below do seem to imply that the daytime impairments from upper airway resistance syndrome (UARS) are suprisingly larger than one might expect, given that it is seen as 'a less severe sleep disordered breathing' problem than obstuctive sleep apnea/hypopnea. BTW UARS is associated with respiratory effort-related arousals (RERAs) and flow limitations...


1: Sleep Med. 2007 Nov 15. [Epub ahead of print] Links
Hypersomnolence, insomnia and the pathophysiology of upper airway resistance syndrome.Gold AR, Gold MS, Harris KW, Espeleta VJ, Amin MM, Broderick JE.
Division of Pulmonary/Critical Care Medicine, Stony Brook University School of Medicine, Stony Brook, DVA Medical Center, Northport, NY 11768, USA.

OBJECTIVE: In order to test the hypothesis that upper airway resistance syndrome (UARS) is merely an extension of the pathophysiology of obstructive sleep apnea/hypopnea (OSA/H) to less severe pharyngeal collapse during sleep, we compared the severity of hypersomnolence and the prevalence of insomnia in UARS patients to the patterns observed for OSA/H patients. Our goal was to determine whether the severity of hypersomnolence and the prevalence of insomnia observed in UARS patients could have been predicted from the patterns observed among OSA/H patients. METHODS: We performed a retrospective study of a large consecutive patient series evaluated at an academic sleep disorders center, including 220 OSA/H patients and 137 UARS patients. Patients had no other sleep-related diagnosis and underwent an initial evaluation that included a measure of hypersomnolence [a multiple sleep latency test (MSLT); 95%] or insomnia questionnaire (87%). Patients were characterized by anthropometric data, polysomnographic descriptive measures of sleep, MSLT data and insomnia questionnaire data. RESULTS: Severity of hypersomnolence decreased over the continuum from severe to mild OSA/H. A model fit to the OSA/H patients to predict severity of hypersomnolence significantly underestimated hypersomnolence in UARS patients, which was comparable in severity to that of patients with mild OSA/H. The frequency of sleep-onset insomnia increased over the continuum from severe to mild OSA/H and increased further in UARS. CONCLUSIONS: UARS is, in some respects, an extension of OSA/H to less severe pharyngeal collapse, but this does not adequately account for the symptom profile of patients with UARS. A physical model is proposed to account for the excess somnolence in UARS relative to expectations and the increasing frequency of sleep-onset insomnia along the continuum from severe OSA/H to UARS.
PMID: 18024168 [PubMed - as supplied by publisher]


1: Sleep Med. 2008 Jan;9(2):121-8. Epub 2007 Jul 17. Links
Differences in clinical features of upper airway resistance syndrome, primary snoring, and obstructive sleep apnea/hypopnea syndrome.Stoohs RA, Knaack L, Blum HC, Janicki J, Hohenhorst W.
Somnolab - Dortmund Sleep Disorders Center, Hörder Burgstr. 18, 44263 Dortmund, Germany. rastoohs@somnolab.de

BACKGROUND: The clinical features of patients with upper airway resistance syndrome (UARS) have previously been compared to patients with obstructive sleep apnea/hypopnea syndrome (OSAHS). No data regarding differences between patients with primary snoring (PS) or patients with obstructive sleep apnea/hypopnea without daytime sleepiness (OSAH) are available. We conducted a study to investigate clinical features of UARS, comparing them to those in patients with PS, OSAH, and OSAHS. METHODS: Retrospective chart analysis of 157 patients with PS, 424 patients with UARS, 562 patients with OSAH, and 1610 patients with OSAHS seen in two sleep disorders clinics between 1996 and 2006. All patients had a diagnostic polysomnography (PSG) and a comprehensive clinical history taken by board-certified sleep specialists. RESULTS: PS and UARS patients were significantly younger, less overweight and had lower weight gain during the past 5years. The female-to-male ratio was highest in the UARS group. UARS patients had significantly less stage non-rapid eye movement sleep (NREM) 1 and NREM 2 and significantly more NREM 3 and NREM 4 sleep than OSAH and OSAHS patients. Arousal indices between PS/UARS and OSAH/OSAHS patients were significantly lower, with no significant difference within these diagnostic categories. Patients with UARS presented the highest degree of subjective impairment. CONCLUSIONS: UARS patients share some clinical features of patients with OSAHS and PS, although these two groups differ in their presentation of clinical sleepiness. Patients with UARS were most impaired in terms of their daily functioning and perception of sleep quality. This finding could not be corroborated by objective measures.

PMID: 17644425 [PubMed - in process]

Edited by Visionary7903, 03 July 2008 - 12:47 PM.


sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

#3 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 05 July 2008 - 02:10 AM

More detail on Dr. Krakow's approach is pasted in below. I have underlined relevant sections which I think follow the general theme of this thread...

http://www.sleepdyna...tance-syndrome/

UARS: A Critical Link to Optimizing PAP Therapy Results
Posted on December 10, 2007 by Dr. Krakow |
I read through some other posts on UARS at www.CPAPTalk.com and frankly, I’m disturbed by a number of comments from individuals who may be inadvertently providing misinformation to this forum.

Having trained with the pioneer researcher Dr. Christian Guilleminault who discovered UARS, I wish to make a few comments that might help PAP therapy users optimize their responses to find high quality sleep.

A reminder that for all practical purposes, the following three terms are interchangeable:

· UARS (upper airway resistance)
· Flow limitation
· RERAs (respiratory effort-related arousals)

UARS as Mini-Suffocations

First and foremost, let’s look at an analogy in cardiology to put to rest the nonsense that UARS does not exist or is somehow not important. We all know that asystole (heart stops) is bad, just as we know apnea (breathing stops) is bad. But, in cardiology, for decades we’ve known there are many other cardiac arrhythmias producing irregular heart rhythms, and we don’t sit back and say, “well it’s not asystole, so it must be OK.” For decades, unfortunately, that practice is in fact what many physicians were taught or conditioned to believe, “it’s not apnea, so it must be OK.” Indeed, to this very day, I still see patients who have been to sleep doctors who told them their sleep study was OK because it didn’t show apneas.

But, as we like to say, “a little choking is still choking,” therefore I think it is reasonable to state that each of the various forms of sleep-disordered breathing (apneas, hypopneas, UARS) reflects some degree of “suffocation.” Apnea is the most concrete form as the patient awakens choking or gasping, whereas UARS is probably equivalent to a “mini-suffocation,” which while asleep I imagine produces an unpleasant sensation but not choking.

UARS is not Mutually Exclusive of Hypopneas or Apneas

Please appreciate then that UARS is simply on the continuum of breathing events. To complete our analogy, UARS represents a more subtle form of breathing irregularity (or as some say pulmonary dysrhythmia). It is not mutually exclusive of apneas or hypopneas. You can have all three types of events when you are diagnosed with sleep-disordered breathing (SDB). In fact, the most common type of SDB shows all 3 components in varying proportions during the sleep study.

You would think though that apneas are more important than UARS events, right? Well, maybe. Don’t forget that UARS events, like apneas, are also frequently associated with sleep fragmentation and therefore unequivocally associated with daytime sleepiness and fatigue. We have seen patients with severe UARS (e.g. RDI > 40), who unequivocally have more sleepiness than say a patient with a moderate degree of apneas and hypopneas (AHI =20). That is why RDI (apneas + hypopneas + UARS) is more valuable when diagnosing and treating your condition than AHI.

To repeat, it is critical to realize that nearly all patients with OSA also have a UARS component on their diagnostic sleep studies, but if the sleep lab doesn’t use the proper respiratory sensors, they will not see it: “what you don’t look for, you will not see!”

UARS Assessment and Treatment is Critical to Titration Success

Still more importantly, when a titration is conducted, UARS is invariably present, because the pressurized airflow doesn’t work like a magic wand to suddenly make apneas disappear. Apneas are often turned into hypopneas as the pressure is increased. Then hypopneas turn into UARS or as more commonly called in the lab nowadays “flow limitation.” Remarkably, many sleep lab techs do not push forward with the titration at this point, believing that their job is done. Even some proportion of sleep medicine physicians do not mandate that their sleep techs increase pressure for flow limitation.

“Consensus Medicine” Covered up The Science of UARS

How anyone would think UARS doesn’t exist or isn’t important probably relates to the sometimes misguided concepts of “conventional wisdom” and “consensus medicine” and how such processes frequently retard scientific discoveries from finding their way into community medical practices. In the early 1980s, papers were published about sleep apnea, then Medicare got on board to accept and cover the condition, after which a new CW was born that’s taken quite awhile to revisit.

Once physicians and patients became accustomed to hearing the words “sleep apnea,” it was only natural that people would block out any other pictures about the nature of a sleep breathing disorder. A consensus formed: either you stop breathing or you don’t! Black and white, eliminate the gray! Which is why we always return to the heart rhythm analogy to help people understand the need to monitor different breathing irregularities, not just apneas.

I have treated thousands of patients with UARS who had either no apneas or hypopneas or an AHI less than 5. Nearly all these patients suffered sleepiness or fatigue from their conditions, and many suffered from insomnia and nocturia. Among those who were able to successfully use an appropriate SDB treatment (e.g PAP therapy, oral appliances, nasal strips, nasal surgery, nasal hygiene and so on.), virtually all achieved clear-cut improvements in their symptoms.

What’s in a Name?

In most of my UARS cases, the patients would almost invariably start the discussion with, “so, you don’t mean I have sleep apnea do you?” Which is interesting, because if you follow the workings of the American Academy of Sleep Medicine, you’ll notice their strategy is to abandon the word UARS, and simply declare that UARS equals sleep apnea. In their lexicon, they would answer the UARS patient as follows, “yes, you have sleep apnea, oh but by the way, you don’t stop breathing.” See the problem? That’s why I continue to use the term UARS to make it clearer to the patient.

As an aside, I’ve seen cases where the UARS was ridiculously subtle (I was almost too embarrassed to call it UARS) or it only appeared in REM sleep. I had to inform these patients that I was skeptical about whether PAP therapy would make any difference. Although I still encouraged this particular subset of patients to give PAP therapy a chance, no more than 50% were willing to try it. Yet, in several cases, some of these patients reported dramatic and sustained (as in years) improvements in fatigue or sleepiness with PAP therapy. Undoubtedly, we find these events very perplexing, but the upshot appears to be that sleep assessment technology for measuring respiration and arousals has a long way to go….but then most of you knew that already!

Start Connecting Some Zzzzzots

Along these lines, let me mention a working theory we have developed about UARS and why bilevel might be the best option for its treatment.

The most salient factor during most titrations is how well the patient responds during expiration. Think about it: it sure feels a lot easier if not pleasurable to breathe in with pressurized airflow coming into your lungs. Many SDB patients are immediately hooked on PAP therapy because of this singular experience.

But breathing out against pressurized airflow is a completely different experience for a very large proportion of patients. After all, it’s downright weird to breathe out when pressurized air is coming in. And, that’s exactly how many people describe it and worse. It’s weird, anxiety-producing, claustrophobic, and triggers a sense of panic. Now, the biggest question is who are the types of UARS patients that would feel so negatively about exhaling on PAP therapy?

In our clinical and research experience, it would be someone who already has some degree of anxiety, a lot or a little, it may not matter, because once they try to use fixed CPAP in particular, they quickly report that it’s very uncomfortable or worse, they report feeling more anxious.

In a large proportion of these patients, we switch them to bilevel during the pre-sleep desensitization/adaptation period, and remarkably, we have found that 90% of these patients report immediate relief by virtue of the lower expiratory pressure.

Note: Bilevel combines IPAP (pressure on Inhalation) and EPAP (pressure dropping on Exhalation).

Can You Feel Anxiety in your Sleep?

Although we have more recently discovered that most patients want to switch to bilevel during the desensitization, that is, before the formal titration begins, we didn’t really figure out this point until we watched UARS patients while asleep. That’s when we saw that they did not like CPAP, that is, a fixed pressure on exhalation. That’s when we saw the ratty looking signal suggesting they were having some kind of anxiety or otherwise unpleasant response to air coming in while they were trying to breathe out.

In my opinion, which I don’t think is shared by the majority of sleep docs, anxiety is experienced while you sleep. If you can experience anxiety in dreams, I don’t see why you can’t experience anxiety to pressurized airflow in your sleep. So, in a nutshell, I think that’s why CPAP doesn’t work well in UARS patients and for that matter, I don’t think it works well in most SDB patients except for truly classic hypersomnolent, anxiety-free, sleep apnea cases.

I think anxiety is already present in the majority of SDB cases, because it is an anxiety-producing experience to breath abnormally all night long. That is, anxiety and breathing are intimately connected, so most SDB patients are more or less conditioned to be more nervous in general by having spent the night not breathing well. Now, introduce a foreign stimulus, CPAP, which then triggers or worsens anxiety by the introduction of an extremely foreign sensation: pressurized airflow forced inward during exhalation.

Is Bilevel the Answer?

Why bilevel works so well is still a puzzle. But, what’s so intriguing is that the subjective and objective findings match. That is, nearly all patients who switch from CPAP to bilevel state that it is easier (subjectively) to breathe out with bilevel. And, during their titrations, the ratty airflow signal disappears on expiration (objectively) and is replaced by a smooth and rounded curve indicating normal expiration.

Should you be able to produce the same results with CFLEX, APAP, etc? Presumably so, except for one “large” difference. You cannot generate the same gradient or gap between IPAP and EPAP with any of the other devices. And, in our clinical and research experience, we are using gaps of 4 to 12 cm of water in our patients. My personal bilevel settings are 21/12.5 for a gap of 8.5.

In our prescriptions for bilevel, I would venture that the average gap is in the 5 to 6 range with tremendous variation, including some with a gap of only 2 or 3. Those with a lower gap requirement would likely do as well on FLEX or APAP, but to repeat, the large majority of our patients have a gap of 4 or greater.

Still, it would be nice to have a respiratory physiologist explain to us why the larger gap is so effective. As an internist and sleep medicine physician, there are only two obvious theories that stand out. First, what if we’ve always assumed, mistakenly, that airway pressure had to be constant for both inspiration and expiration? I think it has already been proven by other researchers that you actually need higher pressure to keep the airway pinned open on inspiration and a lower pressure on expiration. If that’s so, then is bilevel the best system because it provides the exact pressure you need (not too much and not too little) during expiration.

The second idea relates more to the psychophysiological response to PAP therapy. Maybe the larger gradient simply gives the patient a distinctly more comfortable feeling, because the lower pressure creates a feeling so much closer to breathing normally (without PAP). If this theory were accurate, though, it would imply that over time as you get used to any sort of PAP therapy, then perhaps the gap would narrow and eventually you could use fixed CPAP again. If this were true, I would expect more people to eventually adapt to fixed CPAP pressure, and I don’t believe that’s occurring.

UARS Diagnosis and Medicare

Last, insurance coverage for UARS is always a hot topic. This section is not relevant to titrations, because nearly everyone manifests UARS on the titration. Insurance questions revolve around the diagnostic study: does the patient “only” have UARS?

In Albuquerque, I have pushed back on this issue for more than a decade, and the results have been tangible and somewhat satisfying. At this point, there are only 3 insurance carriers in New Mexico who do not cover treatment (specifically, PAP therapy or oral appliances) for UARS. Even among these 3 carriers, we can always make an appeal on very specific comorbidities (e.g. a UARS patient who has had 2 car accidents in the last year), then Medicare might decide to cover such a UARS patient.

In the beginning of this particular journey, I found it frustrating at first, but it was also an opportunity to educate medical directors at insurance companies. We would routinely call these individuals, send them research publications, and explain how UARS was going to cost them more money in the long-run if they didn’t cover it.

As an aside, I have to mention how frustrating and disappointing it is to hear about sleep physicians who might make their decisions about UARS based on insurance considerations. I was never trained to think that way in medical school, and it approaches unethical behavior in my opinion. If a patient is diagnosed with UARS, that’s the diagnosis whether it’s covered by insurance or not. Insurance companies don’t tell me what I can diagnose and they don’t tell me how to treat my patients!

Financial considerations are relevant and important, but they have nothing to do with my patient advocacy and my duty to inform the sleep patient of the diagnosis and treatment plan we recommend.

I am deeply perplexed by the notion that a sleep physician would withhold this information from a UARS patient because the insurance company wasn’t going to cover it. As before, it borders on unethical behavior, in my opinion.

Summing Up

Last and not least, UARS is one of the primary reasons that many SDB patients do not achieve an optimal response. As I describe at length in my book, it is a human tendency to “normalize” behaviors, which over time prevents us from obtaining the best possible response to PAP Therapy. If you are so used to fatigue and sleepiness, having suffered for so many years, then how could you possibly discern what a normal level of sleepiness and fatigue should be? Instead, (and I know this from my own trials from CPAP to APAP and finally bilevel), when you experience some improvement, the tendency is to create a new “normal” and wrongly assume that this is “as good as it gets.”

Well, it’s not as good as it gets if the UARS component of the SDB hasn’t been treated, because there is still more to treat. Undoubtedly, most of the members of this forum recognize the fine-tuning and tweaking that’s needed to manage mask leaks, mask comfort, mouth breathing, humidifier settings, and nasal congestion, just to name a few of the issues that must be regularly attended to enhance the PAP response.

Notwithstanding, in my clinical experience, I have found that resolving the UARS component of SDB is in the top tier of factors that frequently must be addressed to achieve optimal results, especially so among patients whose regular use of PAP therapy has not yielded the desired effects.

I’ve lived through this problem and I’ve breathed through it, and no other single factor enhanced my sleep quality to the level I currently enjoy and am eternally grateful for experiencing.
Surely, this is something to sleep on. I do, night after night.

Flow Limitation and Titrations
Posted on December 5, 2007 by Dr. Krakow |
At CPAPTalk.com, I’ve posted the following to spark some discussion about the lack of attention paid to flow limitation events during titrations:

“I’m curious to know whether most PAP therapy users understand what it means to normalize airflow during your titration test. If you are under the impression that the goal is only to eliminate apneas and hypopneas, then you are missing out on a very important element that might prevent you from attaining the best sleep possible.

Years ago, it was determined that a more subtle form of breathing disturbance known as upper airway resistance (UAR) was an important component of breathing disturbances in patients with sleep apnea. Nowadays, the most common name for UAR in the sleep lab environment is flow limitation, and what’s obvious if you look for it is the need to eliminate flow limitation along with apneas and hypopneas.

At our center, www.sleeptreatment.com, we aggressively seek to find the pressures that normalize the airflow curve, which technically for most patients means that the signal looks very rounded or elliptical while you are breathing in or breathing out. As I mentioned in a previous post, we routinely use bilevel, because we find it much easier to normalize both the inhalation and exhalation airflow curves by using a higher pressure when you breathe in and lower when you breathe out. Nearly all our patients report bilevel is much more comfortable as well.

Most importantly, we have seen many patients who were titrated at other labs, where their lab reports did not mention “flow limitation.” Those labs may have only attempted to titrate out apneas and hypopneas. When we titrated these patients and sought to eliminate flow limitation events, they reported a much deeper sleep.

If you’re curious about flow limitation and whether it might be affecting your sleep, I encourage you to check out my new book, Sound Sleep, Sound Mind at www.soundsleepsoundmind.com. The book has several graphics that show flow limitations and how they differ from apneas and hypopneas. The graphics also show what normal breathing should look like, whether you happen to be a normal sleeper or whether you are getting the optimal response to PAP Therapy.”

Hidden Barriers in Bariatric Surgery
Posted on September 24, 2007 by Dr. Krakow |
This report from the European Respiratory Society highlights two important problems in the way the media and bariatric researchers are framing the discussion about post-operative sleep breathing changes following significant weight loss. First and foremost, they only report the AHI, the apnea-hypopnea index, and not the RDI, the Respiratory Disturbance Index. Thus, it is safe to assume that the researchers did not use advanced respiratory technology to measure UARS events (a.k.a. flow limitation events), the subtle breathing patterns that also provoke sleep fragmentation and subsequent daytime impairment in ways quite similar to classic sleep apnea. The second issue is the comment that the surgical intervention reduced or eliminated snoring in some patients, as if to suggest that snoring is a reliable marker of sleep breathing problems.

In sum, we are faced with the dilemma that both the media and the bariatric researchers are accepting outdated metrics for assessing sleep-disordered breathing (SDB). In the first instance, the assumption is that the AHI tells the whole story. It’s wonderful news to hear that AHI drops post-weight loss, but by not defining and measuring the RDI, it is safe to assume that many of these patients still suffer from SDB that likely needs treatment. The commentary on snoring represents another outdated metric in that we know many patients don’t snore and have SDB, and there are some who do snore and don’t have SDB. Bottom line is that snoring doesn’t tell us a lot about someone’s SDB condition. Again, it’s wonderful news that snoring decreases or disappears with post-op weight loss, and it likely signals that SDB severity has decreased, but it doesn’t tell us whether or not the patient still suffers from SDB, and that is the most important issue in question about the patient’s sleep health.

Imagine if the heart surgeon told a patient, “Looks like we’ve cut down your coronary blockages by 50%.” No intelligent heart patient would be satisfied with such a claim. “Okay, but how much coronary blockage do I still have left?” Same goes for SDB, “how much SDB do these patients still suffer from?” is the question at hand.

Is Treating Snoring Medical Malpractice?
Posted on August 8, 2007 by Dr. Krakow |
In this short video on WebMD, the explicit discussion revolves around one man’s desire for a better night’s sleep, which will somehow be achieved by eliminating his snoring. The treatment he receives is polyester implants into the soft palate for the expressed purpose of stopping the vibrations of these tissues to reduce snoring. What’s the problem here? Actually a very serious one. At no point in the video do we learn whether the patient has been tested with an overnight sleep study (polysomnography) before the surgery or after to evaluate its effects. What would the sleep study show? In all likelihood, the patient has something far more medically significant than snoring; namely, sleep-disordered breathing (SDB), for example, obstructive sleep apnea or upper airway resistance syndrome. The standard of care in the field of sleep medicine requires the patient to undergo a sleep test before and after such treatments to determine to what extent the procedure has improved his condition. Many of these site-specific snoring surgeries provide scant relief of SDB. Some actually worsen SDB. We do not know the patient involved in this video and cannot comment on what he may or may not be suffering from. However, we can state categorically that patients who share some of his features, apparently a long history of snoring, a thick neck, dark circles under his eyes, and most importantly a recessed chin (often covered up by a beard or goatee) frequently test positive on a polysomnogram for obstructive sleep apnea or upper airway resistance syndrome. Was this patient informed of the need for testing before and after surgery? Did the patient receive a full explanation of the risks snoring carries for an SDB diagnosis. Was the patient evaluated by a sleep specialist for a possible SDB diagnosis? If not, then the standard of care established by the field of sleep disorders medicine was not met prior to the surgical intervention.

#4 cmorera

  • Guest
  • 168 posts
  • 0

Posted 06 July 2008 - 04:54 PM

how about caffeine elimination? this seems to significantly block flow literally with reduced bloodflow to the brain, also the 'flow' of neurons by changing them to on always 'on' status.

further, stimulants such as caffeine can alter sleep, especially when consumed in any significant amount, or within 9 hours of bedtime

#5 Rags847

  • Guest
  • 362 posts
  • 25

Posted 06 July 2008 - 05:44 PM

Smoking reduces bloodflow to the brain, too.

#6 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 07 July 2008 - 12:52 PM

how about caffeine elimination? this seems to significantly block flow literally with reduced bloodflow to the brain, also the 'flow' of neurons by changing them to on always 'on' status.

further, stimulants such as caffeine can alter sleep, especially when consumed in any significant amount, or within 9 hours of bedtime


cmorera thanks for the reply and I do agree with the gist of your post - stimulants (including Caffeine) can definitely interfere with sleep quality (see below abstract for example).

I do want to say though that this thread (and the posts above) are focusing on airway flow limitations - I don't think Caffeine will alter those - unless anyone has any evidence otherwise? Caffeine may reduce cerebral blood flow but there is no evidence it would increase airway flow limitations.

Now one can give up Caffeine and all other stimulants but if the breathing flow limitations (partial blockages in the airway causing multiple microarousals in the night) are still there to an abnormal degree, then the root problem will still be there. So you will still have poorer functioning in the daytime even if you 'gave up Caffeine' if the flow limitations are not lowered to a normal level. (Though, as people on the forum have pointed out, giving up regular Caffeine intake may make one's 'baseline' level of daytime mental functioning slightly higher).

1: Sleep Med Rev. 2008 Apr;12(2):153-62. Epub 2007 Oct 18. Links
Caffeine: sleep and daytime sleepiness.
Roehrs T, Roth T.
Sleep Disorders and Research Center, Henry Ford Hospital, 2799 W Grand Blvd, CFP-3, Detroit, MI 48202, USA. taroehrs@aol.com
Caffeine is one of the most widely consumed psychoactive substances and it has profound effects on sleep and wake function. Laboratory studies have documented its sleep-disruptive effects. It clearly enhances alertness and performance in studies with explicit sleep deprivation, restriction, or circadian sleep schedule reversals. But, under conditions of habitual sleep the evidence indicates that caffeine, rather then enhancing performance, is merely restoring performance degraded by sleepiness. The sleepiness and degraded function may be due to basal sleep insufficiency, circadian sleep schedule reversals, rebound sleepiness, and/or a withdrawal syndrome after the acute, over-night, caffeine discontinuation typical of most studies. Studies have shown that caffeine dependence develops at relatively low daily doses and after short periods of regular daily use. Large sample and population-based studies indicate that regular daily dietary caffeine intake is associated with disturbed sleep and associated daytime sleepiness. Further, children and adolescents, while reporting lower daily, weight-corrected caffeine intake, similarly experience sleep disturbance and daytime sleepiness associated with their caffeine use. The risks to sleep and alertness of regular caffeine use are greatly underestimated by both the general population and physicians.
PMID: 17950009 [PubMed - in process]

#7 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 07 July 2008 - 07:19 PM

Now one can give up Caffeine and all other stimulants but if the breathing flow limitations (partial blockages in the airway causing multiple microarousals in the night) are still there to an abnormal degree, then the root problem will still be there. So you will still have poorer functioning in the daytime even if you 'gave up Caffeine' if the flow limitations are not lowered to a normal level. (Though, as people on the forum have pointed out, giving up regular Caffeine intake may make one's 'baseline' level of daytime mental functioning slightly higher).


Too late for an edit to my original post, so I just want to clarify the underlined bit in my quote would be better stated as being 'breathing flow limitations (the subtle breathing patterns that also provoke sleep fragmentation and subsequent daytime impairment in ways quite similar to classic sleep apnea).'

#8 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 13 July 2008 - 09:52 AM

Dr. Barry Krakow on caffeine and the sleep disordered breathing patient...

http://www.sleepdyna...egory/caffeine/

Dark Chocolate, Green Tea and Hypertension
Posted on April 10, 2007 by Dr. Krakow |
The interesting question here is who would be more likely to eat dark chocolate, drink green tea, or suffer from hypertension? The answer is an individual with a sleep disorder and the most likely sleep disorder would be sleep-disordered breathing (SDB). SDB fragments your sleep by causing your brain to repeatedly wake up during repeated episodes of obstructed breathing, which you are not aware of because you are asleep at the time, and you tend to fall back asleep in seconds, so you don’t remember the awakening. This sleep fragmentation causes you to feel tired and sleepy during the day, which prompts many people to seek an energy boost in caffeinated products, such as dark chocolate and green tea. SDB-induced sleep fragmentation also has been linked to hypertension


Caffeine: Miracle Drug or the Best Indicator of Sleep Problems
Posted on December 24, 2007 by Dr. Krakow |
There can be no doubt that caffeine is a miracle drug, because it has probably saved millions of lives by preventing car accidents if not many other workplace accidents. I’m sure physicians have known for years that caffeine enhances work performance in the middle of the night by maintaining necessary degrees of alertness.

So, I’m not knocking caffeine, but in what follows in this post I hope you’ll consider another perspective on caffeine that just might save your life in a way you might not have anticipated.

Let’s start with the fundamental question, “Why do you drink coffee, tea or soda with caffeine?”

Among caffeine users, the single most common answer is, “I like it” and that’s the end of the story.

That’s a fine answer, but I propose that this answer is actually the beginning of the story.

Here are the facts about caffeinated beverage consumption that we see among treatment-seeking sleep patients, which lead us to believe that caffeine use is a marker of something beyond the simple pleasure of enjoying a good cup of coffee and so on:

1. Sleep patients rarely consume these drinks irregularly.
2. Certain types of sleep patients consume more caffeine, on a daily basis, then they are immediately able to measure, that is, they don’t really track it.
3. Most of these sleep patients reach for a caffeine drink during a period of low energy, fatigue or some other state of lower than desired powers of concentration or other mental faculties.
4. Nearly all these sleep patients have spent years engaged in these behaviors.
5. Few of these sleep patients have spent 90 consecutive days, let alone 30 consecutive days, with absolutely no caffeine ingestion.
6. Few have spent a few days or a week without caffeine to help themselves clarify whether there might be a secondary reason for their regular use of the miracle drug.
7. Few sleep patients understand the points made in this list, including the inability to even understand this point, that is, there is something more to understand about caffeine use than simply enjoying it.

So, my view, from my clinical and research experience is that sleep patients have gone so long in using caffeine and see so many people around them engaged in the same behavior, that the only logical conclusion to a caffeine discussion is that “it must be normal.”

This “normalizing” of behavior is one of the greatest barriers to successful treatment of sleep disorders, because sleep patients think everyone sleeps poorly so it too must be “normal.” Caffeine compounds this problem, because caffeine reduces or eliminates the primary symptoms seen in sleep disorders’ patients, namely, sleepiness, fatigue, low energy or poor concentration.

So, yes, caffeine is a miracle drug because it does enhance many behavioral deficits triggered by poor sleep quality or low sleep quantity. Yet, by successfully treating these deficits in the short term, an individual does not connect the dots (or as I say, the “zzzots”) to appreciate that caffeine is covering up a series of symptoms that should in other circumstances lead the individual to seek help for a serious health condition that robs the mind and body of the essential energy needed to function optimally in daily life.

Merry Christmas and please use caffeine to help you drive safely, if necessary tonight.


Caffeine and Miscarriages: MSM Takes a Nap
Posted on January 22, 2008 by Dr. Krakow | 1 Comment
Several MSM articles like this one covered the just released research showing that there is an association between increased caffeine consumption (measured in coffee, sodas or tea) and miscarriage. Like so many studies before it and the coverage on this topic, the MSM is stuck in neutral as it fails to explore other possible explanations for the findings. The findings, after all, are associations, which means that no one is making any claims that caffeine causes miscarriages. Yet, in all the reports I read, most suggest pregnant women should consider reducing caffeine consumption, but few of them actually asked an expert, let alone a sleep expert, to given an alternate view on the findings.

So, here’s mine. It’s well known that caffeine is used to increase energy and ward off fatigue and sleepiness. Thus, it’s not rocket science to make the assumption that a fair number of heavy caffeine users are suffering from fatigue and sleepiness caused by sleep disorders. A potentially common sleep disorder in pregnant women is sleep-disordered breathing, a condition that causes oxidative stress and pro-inflammatory states, and previous research by the inventor of CPAP (the treatment for sleep apnea), Dr. Colin Sullivan, showed a strong link between sleep breathing problems and pre-eclampsia, a condition in pregnancy that may threaten the fetus.

Thus, a parsimonious theory is that pregnant women with sleep apnea are sufficiently tired and sleepy to reach for an extra cup of coffee, etc. So, what the research then really might be showing is that the excess caffeine drinkers actually suffer from undiagnosed sleep disorders, namely sleep-disordered breathing, which through it’s adverse effects on multiple organ systems in the body increases risk for miscarriages.

How the impact of sleep-disordered breathing (SDB) could produce this particular effect is unknown, but SDB causes a great deal of sympathetic nervous system activation by the constant awakenings triggered by disrupted breathing; and the disrupted breathing itself causes marked fluctuations or desaturations in oxygenation throughout the night. Neither of these two processes are considered healthy for the human body, so the most relevant theory would be that these processes are adversely influencing the physiology of pregnancy and the fetus.

#9 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 07 August 2008 - 02:03 PM

1: J Clin Sleep Med. 2007 Mar 15;3(2):133-45.Links
The scoring of arousal in sleep: reliability, validity, and alternatives.
Bonnet MH, Doghramji K, Roehrs T, Stepanski EJ, Sheldon SH, Walters AS, Wise M, Chesson AL Jr.
Dayton Department of Veterans Affairs Medical Center, OH 45428, USA. Bonnet.Michael@dayton.va.gov

The reliability and validity of EEG arousals and other types of arousal are reviewed. Brief arousals during sleep had been observed for many years, but the evolution of sleep medicine in the 1980s directed new attention to these events. Early studies at that time in animals and humans linked brief EEG arousals and associated fragmentation of sleep to daytime sleepiness and degraded performance. Increasing interest in scoring of EEG arousals led the ASDA to publish a scoring manual in 1992. The current review summarizes numerous studies that have examined scoring reliability for these EEG arousals. Validity of EEG arousals was explored by review of studies that empirically varied arousals and found deficits similar to those found after total sleep deprivation depending upon the rate and extent of sleep fragmentation. Additional data from patients with clinical sleep disorders prior to and after effective treatment has also shown a continuing relationship between reduction in pathology-related arousals and improved sleep and daytime function. Finally, many suggestions have been made to refine arousal scoring to include additional elements (e.g., CAP), change the time frame, or focus on other physiological responses such as heart rate or blood pressure changes. Evidence to support the reliability and validity of these measures is presented. It was concluded that the scoring of EEG arousals has added much to our understanding of the sleep process but that significant work on the neurophysiology of arousal needs to be done. Additional refinement of arousal scoring will provide improved insight into sleep pathology and recovery.

PMID: 17557423 [PubMed - indexed for MEDLINE]

#10 Rags847

  • Guest
  • 362 posts
  • 25

Posted 08 August 2008 - 12:09 AM

Visionary (or anyone), how can one know if one has any type of sleep disorder?
Any tests one can do on one's own?
Or do you need to go to a sleep clinic and be tested (how much does that run, $-wise?)

Maybe I should take my video camera, put on the infrared, and videotape myself sleeping (that would be a trip to go back and watch). I think I could only get 90 min or 120 min max of footage, though.

Edited by Rags847, 08 August 2008 - 12:12 AM.


#11 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 12 August 2008 - 10:32 AM

Visionary (or anyone), how can one know if one has any type of sleep disorder?
Any tests one can do on one's own?
Or do you need to go to a sleep clinic and be tested (how much does that run, $-wise?)

Maybe I should take my video camera, put on the infrared, and videotape myself sleeping (that would be a trip to go back and watch). I think I could only get 90 min or 120 min max of footage, though.


Hey Rags

I just want to mention that this thread is trying to focus on sleep disturbances aside from Apneas and Hypopneas which are likely to affect daytime functioning to some degree. They really aren’t always easy to measure. For example even Dr. Barry Krakow admits in blog posts pasted in above: “...but the upshot appears to be that sleep assessment technology for measuring respiration and arousals has a long way to go...”

I myself had a sleep study showing only mildly elevated Apneas/Hypopneas with an Apnea Hypopnea Index (AHI) of 13.6 (less than 5 is normal). On the other hand I had like 33.4 EEG arousals per hour whereas less than 10 I think is normal. I wonder would like none of these arousals per hour be optimal (though I think a normal brain requires at least some ‘arousals’ – I will post more on research in this area another time)?
Anyway first I tried a CPAP and a BiPAP. None of these made a significant difference in my daytime functioning I feel except for a few nights where I tried a cheap and uncomfortable Mandibular Advancement Splint bought off the net, the Somnoguard AP. Now I pushed my lower jaw forward to the maximum degree with the Somnoguard AP and it definitely wasn’t the best thing to do – I could feel my teeth were quite sore the next day. But I did feel more ‘spontaneous’/less ‘robotic’ and more ‘awake’ in the daytime after having it on the night before (even when I slept only 6-7 hours – I usually need a good 8 hours of sleep).

I also tried a CPAP with monitoring readings on it for Apneas and Hypopneas. There were quite a few nights with the CPAP where I got a solid 6-7 hours of use with it on and had an AHI of 4-6 (which is virtually what a ‘normal’ person should have it seems). Anyway to the bemusement of my pharmacist from whom I was hiring the machine, I was still not feeling any better in the daytime/and definitely not as good as I was feeling when I was using the Somnoguard AP.

The thing that has given me sustainable results has been the following combination:
• a high quality expensive but comfortable Mandibular Advancement Splint (the SomnoMed) which moves my lower jaw forward thought not as much as the SomnoGuard AP which had it too far forward (potentially damaging the temporomandibular joint);

• Sleeping with the top of my body/head elevated – just putting my bed on an angle through putting a number of phone books under the one side of the bed. I have read that this method uses gravity to reduce Airway collapse (I will post some studies later). I am actually going to buy a Wedge Pillow which works on the same principle. There is also the possibility that the upper body elevation is working because I have some kind of undiagnosed acid reflux issue and that was interfering with my sleep.

If you cannot afford a sleep study (I am not in the US so dont know the charge over there), I would recommend you try sleeping on the angle and also if you don't notice anything perhaps try buying a cheap Mandibular Advancement Splint like the Somnoguard AP. Try combining the two - I definitely get some results and very consistently. I don't have days where I feel groggy/sleepy anymore though when my energy levels are still not as good as I like sometimes (when I'm not on say Caffeine or other mild stimulants). Prior to this, I used to have days where I was way groggy an hour after getting up even after 8 hours of sleep.

Anyway I am going to have a sleep study done in the middle of next month (with these newly found positive ‘adjustments’) so will let you know of the outcomes and whether my sleep is now virtually ‘normal’.

As far as my symptoms go – I still have ADHD but instead of being inattentive I now feel I have more the combined type. I feel like I can socialise a bit better and have my entire brain ‘with it’ when talking one on one with a person or even carrying on a task. I still have other symptoms like being abnormally at times impulsive, impatient, mentally move from one thing to another (hyperactivity?), slow in following conversations in loud places or in groups, moody, irritable, etc. It feels a bit like Modafinil for me – awake but not necessarily able to focus on a task that needs to be done (though probably not as much energy as Modafinil).

It seems that sleep disturbances were an issue for me though improving them, while definitely helpful, hasn’t nearly cured my ‘ADHD’. There is also the potential that I had sleep disturbances when my brain was developing and that may have caused some kind of permanent brain abnormality (not that my problems are that bad!) - see for example:

1: Neurosci Lett. 2008 Jun 27;438(3):330-4. Epub 2008 Apr 25. Links
Reduced mammillary body volume in patients with obstructive sleep apnea.
Kumar R, Birrer BV, Macey PM, Woo MA, Gupta RK, Yan-Go FL, Harper RM.
Department of Neurobiology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA 90095, USA.
Obstructive sleep apnea (OSA) patients show compromised emotional and cognitive functions, including anterograde memory deficits. While some memory inadequacies in OSA may result from earlier-described structural deficits in the hippocampus, mammillary body injury also could contribute, since these structures receive projections from the hippocampus via the fornix, project heavily to the anterior thalamus, and have been implicated in other conditions with memory deficiencies, such as Korsakoff's syndrome. However, volume loss in mammillary bodies has not been reported in OSA, likely a consequence of logistic difficulties in size assessment. We evaluated mammillary body volumes in 43 OSA (mean age+/-S.D., 46.9+/-9.2 years; mean apnea-hypopnea-index+/-S.D., 31.2+/-19.9events/h) and 66 control subjects (age, 47.3+/-8.9 years). Two high-resolution T1-weighted image volumes were collected on a 3.0T magnetic resonance scanner, averaged to improve signal-to-noise, and reoriented (without warping) into a common space. Brain sections containing both mammillary bodies were oversampled, and the bodies were manually traced and volumes calculated. OSA patients showed significantly reduced left, right, and combined mammillary body volumes compared with control subjects, after partitioning for age, gender, and head size (multivariate linear model, p<0.05). Left-side mammillary bodies showed greater volume reduction than the right side. Diminished mammillary body volume in OSA patients may be associated with memory and spatial orientation deficits found in the syndrome. The mechanisms contributing to the volume loss are unclear, but may relate to hypoxic/ischemic processes, possibly assisted by nutritional deficiencies in the syndrome.
PMID: 18486338 [PubMed - in process]


1: Sleep Breath. 2002 Dec;6(4):205-10. Links
Neonatal intermittent hypoxia impairs dopamine signaling and executive functioning.
Decker MJ, Rye DB.
Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, USA. mdecker@emory.edu
Mesotelencephalic dopamine (DA) pathways are exquisitely vulnerable to ischemic-anoxic insult. These insults are known to produce long-term derangements in DA signaling and have been hypothesized to contribute, at least in part, to pathologic behaviors such as cerebral palsy, schizophrenia, and attention deficit hyperactivity disorder (ADHD). Whether modest intermittent hypoxia, such as that encountered with repetitive apneas in premature infants, contributes to clinically significant impairments in DA signaling, and how these impairments manifest at a systems level, is unknown. To address these voids there is a need to develop animal models emulating features of a common disorder of prematurity, namely, apnea with hypoxia. Behavioral traits exhibited by such models include disturbed sleep-wake architecture, excessive locomotion, and impaired working memory persisting 1 to 2 months post-insult. Western-blot analysis of expression patterns of proteins involved in DA signaling (e.g., DA and vesicular monoamine transporters, tyrosine hydroxylase, and D1 receptors) are consistent with that which might be expected from hyper- or hypodopaminergic functioning in DA-responsive prefrontal cortex and striatal circuits, respectively. These novel observations suggest that intermittent hypoxia occurring during a period of critical brain development disrupts development of those mesotelencephalic pathways modulating the expression of sleep and wakefulness, locomotion, and executive functioning.
PMID: 12524574 [PubMed - indexed for MEDLINE]


I am thinking that there is a whole ‘chicken and egg’ thing with the ‘sleep and mental functioning’ relationship – poor sleep may cause some mental functioning issues and mental functioning issues may cause poor sleep. For example, look at the study below where a malfunctioning hypothalamo-pituitary-adrenal axis may contribute to the development of chronic noise-related sleep disturbances (and indeed a lot of people with ADHD for example have a malfunctioning HPA axis and also sleep better with a white noise machine to mask any noise):

1: J Am Assoc Lab Anim Sci. 2007 Jan;46(1):35-41.Links
Extra-auditory effects of noise in laboratory animals: the relationship between noise and sleep.Rabat A.
Research Department, Institute of Naval Medicine for the French Health Service of Armed Forces, Army Teaching Hospital, Saint Anne, France. a.rabat@imnssa.net

Noise has both auditory and extra-auditory effects. Some of the most deleterious extra-auditory effects of noise are those leading to sleep disturbances. These disturbances seem to be related to both endogenous (physical parameters) and exogenous (sex, age) factors of noise. Despite correlative relations between noise level and awakenings, the scientific community has not reached consensus regarding a specific action of these factors on the different sleep stages. In animal research, 2 complementary main fields of research exist. One is focused on the positive modulation of sleep by repeated tone stimulation. The other concerns noise-related sleep disturbances. The few studies that have investigated noise-related sleep disturbances suggest the following conclusions. First, sleep disturbances are greater upon exposure to environmental noise, whose frequency spectrum is characterized by high and ultrasonic sounds, than white noise. Second, unpredictability and pattern of noise events are responsible for extractions from both SWS and PS. Third, chronic exposure to noise permanently reduces and fragments sleep. Finally, in chronic noise exposure, an inter-individual variability in SWS deficits is observed and correlated to a psychobiological profile related to an incapability to face stressful situations. Based on results from other research, acute noise-related sleep perturbations could result from an imbalance in the sleep-wake cycle in favor of arousing ascending systems. Chronic noise-related sleep disturbances may arise due to imbalance of the sleep-wake cycle and malfunctioning of the hypothalamo-pituitary-adrenal axis which may both contribute to the development of pathology.

PMID: 17203914 [PubMed - indexed for MEDLINE]

#12 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 20 September 2008 - 12:47 PM

As far as my symptoms go – I still have ADHD but instead of being inattentive I now feel I have more the combined type. I feel like I can socialise a bit better and have my entire brain ‘with it’ when talking one on one with a person or even carrying on a task. I still have other symptoms like being abnormally at times impulsive, impatient, mentally move from one thing to another (hyperactivity?), slow in following conversations in loud places or in groups, moody, irritable, etc. It feels a bit like Modafinil for me – awake but not necessarily able to focus on a task that needs to be done (though probably not as much energy as Modafinil).

It seems that sleep disturbances were an issue for me though improving them, while definitely helpful, hasn’t nearly cured my ‘ADHD’. There is also the potential that I had sleep disturbances when my brain was developing and that may have caused some kind of permanent brain abnormality (not that my problems are that bad!) - see for example:

1: Neurosci Lett. 2008 Jun 27;438(3):330-4. Epub 2008 Apr 25. Links
Reduced mammillary body volume in patients with obstructive sleep apnea.
Kumar R, Birrer BV, Macey PM, Woo MA, Gupta RK, Yan-Go FL, Harper RM.
Department of Neurobiology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA 90095, USA.
Obstructive sleep apnea (OSA) patients show compromised emotional and cognitive functions, including anterograde memory deficits. While some memory inadequacies in OSA may result from earlier-described structural deficits in the hippocampus, mammillary body injury also could contribute, since these structures receive projections from the hippocampus via the fornix, project heavily to the anterior thalamus, and have been implicated in other conditions with memory deficiencies, such as Korsakoff's syndrome. However, volume loss in mammillary bodies has not been reported in OSA, likely a consequence of logistic difficulties in size assessment. We evaluated mammillary body volumes in 43 OSA (mean age+/-S.D., 46.9+/-9.2 years; mean apnea-hypopnea-index+/-S.D., 31.2+/-19.9events/h) and 66 control subjects (age, 47.3+/-8.9 years). Two high-resolution T1-weighted image volumes were collected on a 3.0T magnetic resonance scanner, averaged to improve signal-to-noise, and reoriented (without warping) into a common space. Brain sections containing both mammillary bodies were oversampled, and the bodies were manually traced and volumes calculated. OSA patients showed significantly reduced left, right, and combined mammillary body volumes compared with control subjects, after partitioning for age, gender, and head size (multivariate linear model, p<0.05). Left-side mammillary bodies showed greater volume reduction than the right side. Diminished mammillary body volume in OSA patients may be associated with memory and spatial orientation deficits found in the syndrome. The mechanisms contributing to the volume loss are unclear, but may relate to hypoxic/ischemic processes, possibly assisted by nutritional deficiencies in the syndrome.
PMID: 18486338 [PubMed - in process]


1: Sleep Breath. 2002 Dec;6(4):205-10. Links
Neonatal intermittent hypoxia impairs dopamine signaling and executive functioning.
Decker MJ, Rye DB.
Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, USA. mdecker@emory.edu
Mesotelencephalic dopamine (DA) pathways are exquisitely vulnerable to ischemic-anoxic insult. These insults are known to produce long-term derangements in DA signaling and have been hypothesized to contribute, at least in part, to pathologic behaviors such as cerebral palsy, schizophrenia, and attention deficit hyperactivity disorder (ADHD). Whether modest intermittent hypoxia, such as that encountered with repetitive apneas in premature infants, contributes to clinically significant impairments in DA signaling, and how these impairments manifest at a systems level, is unknown. To address these voids there is a need to develop animal models emulating features of a common disorder of prematurity, namely, apnea with hypoxia. Behavioral traits exhibited by such models include disturbed sleep-wake architecture, excessive locomotion, and impaired working memory persisting 1 to 2 months post-insult. Western-blot analysis of expression patterns of proteins involved in DA signaling (e.g., DA and vesicular monoamine transporters, tyrosine hydroxylase, and D1 receptors) are consistent with that which might be expected from hyper- or hypodopaminergic functioning in DA-responsive prefrontal cortex and striatal circuits, respectively. These novel observations suggest that intermittent hypoxia occurring during a period of critical brain development disrupts development of those mesotelencephalic pathways modulating the expression of sleep and wakefulness, locomotion, and executive functioning.
PMID: 12524574 [PubMed - indexed for MEDLINE]


http://www.scienceda...41025124027.htm

Reductions In Blood Oxygen Levels In Newborns Could Contribute To ADHD Development
ScienceDaily (Oct. 26, 2004) — SAN DIEGO -- A repetitive drop in blood oxygen levels in newborn rats, similar to that caused by apnea (brief pauses in breathing) in some human infants, is followed by a long-lasting reduction in the release of the brain neurotransmitter dopamine, according to an Emory University research study. Because dopamine promotes attention, learning, memory and a variety of higher cognitive functions, the researchers believe repetitive apnea during neonatal development may be one factor leading to the development of attention deficit hyperactivity disorder (ADHD). This research will be reported at the Society for Neuroscience annual meeting in San Diego on October 24 by Glenda Keating, PhD, and Michael Decker, PhD, of the Department of Neurology at Emory University's School of Medicine. The research was funded by the National Heart Lung and Blood Institute and conducted by the Program in Sleep Medicine and the Department of Neurology at Emory University.

Apnea of prematurity occurs in up to 85 percent of all prematurely born human infants, and obstructive sleep apnea occurs in 3 to 27 percent of all children. Data from previous studies suggests that diminished release of brain dopamine may be responsible for behaviors such as impulsiveness and distractibility, reduced self control, and impaired learning, which are hallmark traits associated with ADHD. Previous studies in Dr. Decker's laboratory at Emory have shown that newborn rats who experience repetitive drops in blood oxygen levels go on to develop behavioral traits similar to those seen in humans with ADHD. This is the first time, however, that researchers have linked repetitive reductions in blood oxygen levels during a period of critical brain development to long-lasting deficiencies in release of dopamine specifically within the striatum, which is one of the brain regions important in modulating behavior, learning and memory.

The scientists exposed newborn rats from 7 to 11 days old to either 20-second bursts of a gas containing low oxygen content or to bursts of compressed air. Once the rats matured into juveniles, the scientists studied their locomotive activity and brain dopamine levels. They found that juvenile rats exposed to brief reductions in oxygen during their neonatal period had a 50 percent reduction in release of dopamine and were hyperactive.

Traditionally, ADHD has been attributed to genetic causes, environmental toxins or maternal use of nicotine, alcohol or drugs. Also, researchers generally have believed that the newborn brain is somewhat resistant to subtle disturbances in blood oxygenation. This study demonstrates in rats, however, that while long-term decreases in the release of dopamine can occur following as few as five days of subtle, repetitive reductions in blood oxygen levels during a critical window of brain development, the hyperactivity and impaired learning that also occur are not noticeable until later, when juvenile animals are old enough to display these behaviors.

The Emory scientists found that juvenile rats exposed to repetitive drops in blood oxygen levels as newborns also had a 50 percent increase in the level of dopamine stored in the brain tissue of the striatum compared to control rats and a reduction in the release of dopamine, showing that instead of releasing dopamine, they were abnormally storing it.

"By linking reductions in blood oxygen during critical times of development to changes in dopamine function, we hope to shed light on the mechanisms of ADHD, which have been poorly understood to this point," said Dr. Keating. "Our results show that a relatively common occurrence in newborns could have long-lasting negative effects, and we believe our model has great potential for creating new insights and leading to new interventions and therapies."

"Our research also could help explain why amphetamines, such as Ritalin, and other non-amphetamines, such as Wellbutrin, that increase levels of brain dopamine are an effective treatment for children with ADHD," Dr. Decker said. "So far scientists haven't sorted out which neurotransmitters are responsible for this effect, but if that could be narrowed down to just dopamine, as suggested by our data, it would provide a basis for developing drugs without the potential addictive properties of existing therapies."

The Emory investigators are exploring different ways to measure altered behavioral outcomes in rats to further confirm the similarity of these behaviors to those identified in ADHD. They also are planning studies aimed at preserving the brain dopamine system in individuals at risk for repetitive reductions in blood oxygenation. These studies could include non-invasive, subtle dietary changes in the mother and the newborn.


--------------------------------------------------------------------------------

Adapted from materials provided by Emory University Health Sciences Center.

#13 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 08 November 2008 - 04:27 AM

For the below studies, I am not sure whether the type of ‘fats’ eaten makes a difference. Would eating ‘good fatty foods’ like Sockeye Salmon, Avocado or Olives at dinner time negatively influence the sleep pattern of healthy adults?


http://sleepmeeting....ke-you-eat.html

Tuesday, June 10, 2008
Do You Sleep Like You Eat?
Two studies from Brazil that are being presented as poster presentation this morning at SLEEP 2008 address the relationship between your sleep and the food you eat. Both studies involved 52 healthy subjects between the ages of 20 and 45 years.

One study (ID# 0084) found that both total energy intake and late-night snack energy intake are significantly correlated with awakenings during sleep. Both measures of energy intake also were correlated with apnea-hypopnea index, a measurement of the severity of obstructive sleep apnea.

Another study (ID# 0085) found that total fat intake is related to a number of sleep measures, including percentage of REM sleep, arousal index and apnea-hypopnea index. The study also found that fat intake at dinner is associated with sleep measures such as sleep efficiency and REM percentage. The results show that total fat intake and dinner fat intake seem to have a negative influence on the sleep pattern of healthy adults.

The SLEEP 2008 abstract book is available online at http://www.journalsl...actBook2008.pdf.


1: Nutr Neurosci. 2008 Aug;11(4):146-54. Links
Acute effects of the very low carbohydrate diet on sleep indices.
Afaghi A, O'Connor H, Chow CM.
Discipline of Exercise and Sport Science, Faculty of Health Sciences, The University of Sydney, Sydney, New South Wales, Australia; School of Medicine, Qazvin University of Medical Science, Qazvin, Iran.
OBJECTIVE: We compared the effect of short-term consumption of a very low carbohydrate (VLC) diet over 48 h to a control mixed diet on sleep indices in healthy, non-obese men. DESIGN: This study employed a repeated-measure design where subjects were given isocaloric (2400 kcal) diets and matching evening test meals (4 h before usual bed-time), which were either mixed low-fat, high carbohydrate (15.5%, 12.5% and 72% of energy from protein, fat and carbohydrate, respectively) or VLC (38%, 61% and < 1% of energy from protein, fat and carbohydrate, respectively). Polysomnographic testing was performed on the familiarization and control night, 4 h after the first VLC test meal (acute phase) and 48 h (ketosis phase) following commencement of the VLC diet. SUBJECTS: Fourteen healthy, non-obese men (aged 18-35 years; body mass index 23.4 +/- 1.9 kg/m(2)) who were good sleepers took part in the study. MEASUREMENT: Objective sleep was recorded using a computerized sleep system. Urine ketone level was monitored with reagent strips before the evening test meals and at bed-time on the control night, during the VLC acute and ketosis phases. Blood glucose level was measured with a glucometer before the evening test meal until 120 min following the meal. Hunger and fullness were assessed immediately after the meal until bed-time with Likert scales. RESULTS: The proportion of rapid-eye movement (REM) sleep to total sleep time was significantly reduced at the VLC acute and VLC ketosis when compared to the control night (P = 0.006; n = 11 and P = 0.05; n = 14, respectively). The percentage of slow wave sleep (SWS) significantly increased for both the VLC acute (17.7 +/- 6.7) and ketosis (17.8 +/- 6.1) phases compared to control (13.9 +/- 6.3), P = 0.02 for both phases. CONCLUSIONS: In healthy, good sleepers, the VLC diet over the short-term promotes increases in the percentage of SWS (deep sleep stage 4) and a reduction in the percentage of REM sleep ('dreaming' sleep) compared to the control mixed diet. The sleep changes may be linked to the metabolism of the fat content of the VLC diet.PMID: 18681982 [PubMed - in process]

#14 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 15 March 2009 - 06:17 AM

Would love to see the full text of the below study and specifically the details of the "multicomponent sleep intervention" for youth with Bipolar disorder that is mentioned...


1: Child Adolesc Psychiatr Clin N Am. 2009 Apr;18(2):321-38, viii. Links
The adverse consequences of sleep disturbance in pediatric bipolar disorder: implications for intervention.Harvey AG.
Department of Psychology, University of California-Berkeley, Berkeley, CA 94720-1650, USA. aharvey@berkeley.edu

Bipolar disorder (BPD) is a severe and chronic disorder, ranked among the top 10 leading causes of disability worldwide. Bipolar spectrum disorders with onset in childhood and adolescence have a particularly severe course, including more suicide attempts and greater comorbidity. The evidence accrued to date indicates that sleep disturbances are common among youth with BPD. Moreover, sleep problems may be an early marker for BPD, a distinguishing feature of BPD, and a contributor to relapse. The evidence reviewed highlights that sleep problems are associated with a range of serious adverse consequences, including difficulty in regulating affect in the daytime and difficulties with cognitive functions, such as memory, learning, attention, and concentration. Evidence reviewed also points to sleep disturbance as one possible contributor to weight gain, comorbid substance use, and impulsivity. The implications for intervention are explored, and a multicomponent sleep intervention for youth with BPD is outlined.

PMID: 19264266 [PubMed - in process]

#15 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 01 April 2009 - 12:00 PM

Has anyone experimented just before going to bed with high doses (and preferably timed release) versions of anti-inflammatories that work for example to inhibit 5-lipoxygenase? See studies below for my reasoning...
I would imagine a fair chunk of the people coming on this forum who have 'brain fog' might have MILD sleep disordered breathing as an important side issue (or even a root reason for some) for their problem.
Instead of recommending they go on Ritalin/Adderrall/Modafinil/etc, why not also suggest experimenting with substances that reduce inflammation during sleep. Substances that reduce inflammation during sleep + a mandibular advancement device might really take things to the next level in terms of their daily functioning...


1: Chest. 2006 Jul;130(1):143-8. Links
Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome.

Goldbart AD, Krishna J, Li RC, Serpero LD, Gozal D.
Kosair Children's Hospital Research Institute, University of Louisville, 570 South Preston St, Suite 321, Louisville, KY 40202, USA.
BACKGROUND: Upper airway inflammation is now recognized in adults with obstructive sleep apnea (OSA) syndrome. However, the role played by eicosanoids such as leukotrienes and prostaglandins is unclear. OBJECTIVE: To investigate whether eicosanoids are measurable in exhaled breath condensate (EBC), and to determine whether differences in these inflammatory mediators emerge among children with and without sleep-disordered breathing (SDB). METHODS: EBC was collected from 50 consecutive snoring children undergoing overnight polysomnography for suspected SDB, and from 12 nonsnoring control subjects. Prostaglandin E2 (PGE2), leukotriene B4 (LTB4), and cysteinyl leukotrienes (cys-LTs: leukotriene C4 [LTC4]/leukotriene D4 [LTD4]/leukotriene E4 [LTE4]) EBC levels were analyzed using enzyme-linked immunosorbent assay. RESULTS: LTB4 levels were elevated in children with an apnea-hypopnea index (AHI) > 5/h (SDB; 97.6 +/- 6.3 pg/mL) compared to children with an AHI < 5/h (mild SDB; 66.4 +/- 19.1 pg/mL; p < 0.01) and control subjects (27.8 +/- 3.7 pg/mL; p < 0.01). Similarly, cys-LT (LTC4/LTD4/LTE4) concentrations were also increased in SDB (45.1 +/- 10.6 pg/mL in SDB vs 27.6 +/- 8.3 pg/mL in mild SDB, and 15.7 +/- 7.6 pg/mL in control subjects; p < 0.01). In contrast, PGE2 concentrations were similar among the three groups. CONCLUSIONS: Inflammatory mediators such as leukotrienes and prostaglandins can be readily quantified in EBC collected from the upper airway of children. Disease severity-dependent increases in leukotriene concentrations (LTB4 and LTC4/LTD4/LTE4) emerge among children and may serve as a noninvasive tool in the clinical assessment of these children.
PMID: 16840394 [PubMed - indexed for MEDLINE]



1: Chest. 2009 Jan 13. [Epub ahead of print] Links
Urine Concentrations of Cysteinyl Leukotrienes in Children With Obstructive Sleep-Disordered Breathing.

Kaditis AG, Alexopoulos E, Chaidas K, Ntamagka G, Karathanasi A, Tsilioni I, Kiropoulos TS, Zintzaras E, Gourgoulianis K.
From the Sleep Disorders Laboratory (Drs. Kaditis, Alexopoulos, Chaidas, Ntamagka, Karathanasi, and Gourgoulianis, Ms. Tsilioni, and Mr. Kiropoulos) and the Department of Biomathematics (Dr. Zintzaras), University of Thessaly School of Medicine and Larissa University Hospital, Larissa, Greece.
Background Adenotonsillar tissue of children with obstructive sleep-disordered breathing (SDB) has increased content of cysteinyl leukotrienes (CysLTs) and expression of CysLTs receptors. Furthermore, CysLTs concentrations in the nasal exhaled breath condensate of children with sleep apnea are elevated. Objective To investigate the relationship between urine levels of CysLTs and severity of SDB in children. Methods Morning urine concentrations of CysLTs were measured in children with symptoms of SDB and in controls with recurrent tonsillitis and without snoring who underwent polysomnography and were expressed in pg/mL per mg/dL of urine creatinine. Results Nineteen children with moderate-to-severe SDB (mean age +/- SD: 5.4 +/- 1.6 years; obstructive apnea-hypopnea index-OAHI: 14.4 +/- 9.6 episodes/hour), 29 subjects with mild SDB (5.1 +/- 1.5 years; OAHI: 2.9 +/- 0.8 episodes/hour), 26 children with primary snoring (7 +/- 2.6 years; OAHI: 1.1 +/- 0.3 episodes/hour) and 18 control subjects (6.4 +/- 2.5 years; OAHI: 0.7 +/- 0.3 episodes/hour) were studied. Children with moderate-to severe SDB had higher log-transformed urine CysLTs levels than those with mild SDB, primary snoring or controls (2.39 +/- 0.51 vs 2.06 +/- 0.26 vs 2.11 +/- 0.25 vs 1.86 +/- 0.28; p < 0.05). Log-transformed CysLTs concentration, tonsillar size and body mass index z score were significant predictors of log-transformed OAHI (p < 0.01). Conclusions Urine excretion of CysLTs is related to SDB severity in children. This finding indicates that 5-lipoxygenase pathway products participate in the pathogenesis of obstructive sleep apnea in childhood or alternatively that SDB promotes CysLTs biosynthesis.


PMID: 19141528 [PubMed - as supplied by publisher]

#16 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 06 April 2009 - 10:13 AM

Has anyone experimented just before going to bed with high doses (and preferably timed release) versions of anti-inflammatories that work for example to inhibit 5-lipoxygenase? See studies below for my reasoning...
I would imagine a fair chunk of the people coming on this forum who have 'brain fog' might have MILD sleep disordered breathing as an important side issue (or even a root reason for some) for their problem.
Instead of recommending they go on Ritalin/Adderrall/Modafinil/etc, why not also suggest experimenting with substances that reduce inflammation during sleep. Substances that reduce inflammation during sleep + a mandibular advancement device might really take things to the next level in terms of their daily functioning...


1: Chest. 2006 Jul;130(1):143-8. Links
Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome.

Goldbart AD, Krishna J, Li RC, Serpero LD, Gozal D.
Kosair Children's Hospital Research Institute, University of Louisville, 570 South Preston St, Suite 321, Louisville, KY 40202, USA.
BACKGROUND: Upper airway inflammation is now recognized in adults with obstructive sleep apnea (OSA) syndrome. However, the role played by eicosanoids such as leukotrienes and prostaglandins is unclear. OBJECTIVE: To investigate whether eicosanoids are measurable in exhaled breath condensate (EBC), and to determine whether differences in these inflammatory mediators emerge among children with and without sleep-disordered breathing (SDB). METHODS: EBC was collected from 50 consecutive snoring children undergoing overnight polysomnography for suspected SDB, and from 12 nonsnoring control subjects. Prostaglandin E2 (PGE2), leukotriene B4 (LTB4), and cysteinyl leukotrienes (cys-LTs: leukotriene C4 [LTC4]/leukotriene D4 [LTD4]/leukotriene E4 [LTE4]) EBC levels were analyzed using enzyme-linked immunosorbent assay. RESULTS: LTB4 levels were elevated in children with an apnea-hypopnea index (AHI) > 5/h (SDB; 97.6 +/- 6.3 pg/mL) compared to children with an AHI < 5/h (mild SDB; 66.4 +/- 19.1 pg/mL; p < 0.01) and control subjects (27.8 +/- 3.7 pg/mL; p < 0.01). Similarly, cys-LT (LTC4/LTD4/LTE4) concentrations were also increased in SDB (45.1 +/- 10.6 pg/mL in SDB vs 27.6 +/- 8.3 pg/mL in mild SDB, and 15.7 +/- 7.6 pg/mL in control subjects; p < 0.01). In contrast, PGE2 concentrations were similar among the three groups. CONCLUSIONS: Inflammatory mediators such as leukotrienes and prostaglandins can be readily quantified in EBC collected from the upper airway of children. Disease severity-dependent increases in leukotriene concentrations (LTB4 and LTC4/LTD4/LTE4) emerge among children and may serve as a noninvasive tool in the clinical assessment of these children.
PMID: 16840394 [PubMed - indexed for MEDLINE]



1: Chest. 2009 Jan 13. [Epub ahead of print] Links
Urine Concentrations of Cysteinyl Leukotrienes in Children With Obstructive Sleep-Disordered Breathing.

Kaditis AG, Alexopoulos E, Chaidas K, Ntamagka G, Karathanasi A, Tsilioni I, Kiropoulos TS, Zintzaras E, Gourgoulianis K.
From the Sleep Disorders Laboratory (Drs. Kaditis, Alexopoulos, Chaidas, Ntamagka, Karathanasi, and Gourgoulianis, Ms. Tsilioni, and Mr. Kiropoulos) and the Department of Biomathematics (Dr. Zintzaras), University of Thessaly School of Medicine and Larissa University Hospital, Larissa, Greece.
Background Adenotonsillar tissue of children with obstructive sleep-disordered breathing (SDB) has increased content of cysteinyl leukotrienes (CysLTs) and expression of CysLTs receptors. Furthermore, CysLTs concentrations in the nasal exhaled breath condensate of children with sleep apnea are elevated. Objective To investigate the relationship between urine levels of CysLTs and severity of SDB in children. Methods Morning urine concentrations of CysLTs were measured in children with symptoms of SDB and in controls with recurrent tonsillitis and without snoring who underwent polysomnography and were expressed in pg/mL per mg/dL of urine creatinine. Results Nineteen children with moderate-to-severe SDB (mean age +/- SD: 5.4 +/- 1.6 years; obstructive apnea-hypopnea index-OAHI: 14.4 +/- 9.6 episodes/hour), 29 subjects with mild SDB (5.1 +/- 1.5 years; OAHI: 2.9 +/- 0.8 episodes/hour), 26 children with primary snoring (7 +/- 2.6 years; OAHI: 1.1 +/- 0.3 episodes/hour) and 18 control subjects (6.4 +/- 2.5 years; OAHI: 0.7 +/- 0.3 episodes/hour) were studied. Children with moderate-to severe SDB had higher log-transformed urine CysLTs levels than those with mild SDB, primary snoring or controls (2.39 +/- 0.51 vs 2.06 +/- 0.26 vs 2.11 +/- 0.25 vs 1.86 +/- 0.28; p < 0.05). Log-transformed CysLTs concentration, tonsillar size and body mass index z score were significant predictors of log-transformed OAHI (p < 0.01). Conclusions Urine excretion of CysLTs is related to SDB severity in children. This finding indicates that 5-lipoxygenase pathway products participate in the pathogenesis of obstructive sleep apnea in childhood or alternatively that SDB promotes CysLTs biosynthesis.


PMID: 19141528 [PubMed - as supplied by publisher]




Cyclooxygenase 2 and intermittent hypoxia-induced spatial deficits in the rat
Richard C Li, Barry W Row, Evelyne Gozal, Leila Kheirandish, et al. American Journal of Respiratory and Critical Care Medicine. New York: Aug 15, 2003. Vol. 168, Iss. 4; pg. 469
Abstract (Summary)
Intermittent hypoxia (IH) during sleep, a critical feature of sleep apnea, induces significant neurobehavioral deficits in the rat. Cyclooxygenase (COX)-2 is induced during stressful conditions such as cerebral ischemia and could play an important role in IH-induced learning deficits. We therefore examined COX-1 and COX-2 genes and COX-2 protein expression and activity (prostaglandin E2 [PGE2] tissue concentration) in cortical regions of rat brain after exposure to either IH (10% O2 alternating with 21% O2 every 90 seconds) or sustained hypoxia (10% O2). In addition, the effect of selective COX-2 inhibition with NS-398 on IH-induced neurobehavioral deficits was assessed. IH was associated with increased COX-2 protein and gene expression from Day 1 to Day 14 of exposure. No changes were found in COX-1 gene expression after exposure to hypoxia. IH-induced COX-2 upregulation was associated with increased PGE2 tissue levels, neuronal apoptosis, and neurobehavioral deficits. Administration of NS-398 abolished IH-induced apoptosis and PGE2 increases without modifying COX-2 mRNA expression. Furthermore, NS-398 treatment attenuated IH-induced deficits in the acquisition and retention of a spatial task in the water maze. We conclude that IH induces upregulation and activation of COX-2 in rat cortex and that COX-2 may play a role in IH-mediated neurobehavioral deficits.

From the full text of this paper:
"DISCUSSION

In this study, we found that COX2 mRNA was induced by IH and CH [chronic hypoxia], albeit to a greater magnitude and duration in the earlier compared with the latter. In contrast, COX-2 protein expression was only increased after intermittent hypoxic exposures of freely behaving rats during their sleep circadian phase. These changes were associated with corresponding increases in PGE2 concentrations in cortical tissue. Furthermore, administration of the selective COX2 inhibitor NS-398 not only abolished the enhanced generation of PGE2 but also attenuated IH-induced apoptosis and neurobehavioral deficits, suggesting that the latter are, at least in part, due to increased expression of COX-2 in the brain.

The original assumption, based on work with inflammation cells, was that COX-1 was necessary to produce low basal amounts of prostaglandins for physiologic purposes, whereas the inducible COX-2 generated prostanglandins in larger amounts and contributed to tissue injury. This view appears to have been substantially challenged in recent years, as mice lacking COX-2 display significant renal abnormalities (22) and COX-2-derived products are produced by the normal vasculature (23) and are required for successful reproduction (24). Furthermore, COX-2 is constitutively expressed in neurons (3) and is dynamically regulated by physiologic synaptic activity (4, 5). These observations together with additional evidence supporting a role for COX-2 in spatial memory consolidation (25) suggest that COX-2 is an important modulator of neuronal function during physiologic conditions. However, in conditions leading to COX-2 induction, such as repeated spreading depression (26, 27), stroke (6, 12, 13), or excitotoxicity induced by glutamatergic agonists (11, 28-31), COX-2 activity appears to play a critical role in neuronal cell injury and death. Because hypoxia leads to excessive release of glutamate (32, 33) and activation of glutamatergic receptors in the brain that in turn can induce COX-2 (30) and because the opposite is also possible (i.e., COX-2 activation by hypoxia can lead to release of glutamate) (34), we focused our attention on the changes in COX-2 expression and activity after exposure during the lights-on period to our recently developed IH model of sleep-disordered breathing. Of note, this model employs a relatively mild hypoxic stimulus that is not associated with either behavioral or metabolic evidence of cellular energy limitation (2). However, to establish further whether mild hypoxia or whether the mode of presentation of the mild hypoxic stimulus were of importance in the process of inducing COX-2 in rat brain cortex, we incorporated CH exposures of similar magnitude to the experimental design. Our findings indicate that IH leads to an induction of COX-2 mRNA and upregulation of COX-2 protein, resulting in substantial increases in PGE2 production. Thus, the cyclical nature of hypoxia during sleep, rather than hypoxia per se, may lead to increased oxidative stress (35), and the latter may underlie the signaling pathways mediating COX-2 induction. One possible explanation for the discrepancy between IH and CH could relate to either difference in the oxidative stress each of these hypoxic stimuli generates, or alternatively, the differences in COX-2 induction between IH and CH could represent post-translational modifications associated with adaptation processes. In addition, IH could be associated with upregulation of proin-flammatory cylokines, which would in turn lead to increased COX-2 expression (36). In support of the latter contention, we found that IH, but not CH, elicit increased mRNA expression of interleukin-1 in cortical tissue (data not shown).

There is increasing evidence that COX-2 is involved in the pathogenesis of several neurologic disorders including cerebral ischemia (10, 11, 13-15, 17), traumatic brain injury (37-41), and Alzheimer disease (7, 8). Cerebral ischemia is associated with prominent upregulation of COX-2 in neurons, inflammatory cells, glial cells, and the vasculature (3, 10, 14, 42) and administration of the selective COX-2 inhibitor, NS-398, or genetic deletion of COX-2 in mice will substantially attenuate cerebral ischemic injury (11, 12, 15-18), suggesting that COX-2 is mechanistically involved in the mechanisms leading to cerebral ischemic injury.

In preliminary studies, we found that the nadir of IH-induced spatial learning deficits occurred at 7 days of exposure, and therefore, we selected this time point for the COX-2 inhibitor experiments. To further establish relationships between IH-induced COX-2 and IH-induced neurobehavioral deficits, animals were treated with NS-398, a selective COX-2 inhibitor with 168 times higher affinity for COX-2 compared with COX-1 (20). NS398 attenuated COX-2-mediated neurotoxicity in vitro by blocking lipopolysaccharide-induced elevation of PGE2 (43, 44) as well as NMDA excitotoxicity (27, 31, 45, 46). Similarly, in vivo treatment with NS398 reduced the infarct size after occlusion of middle cerebral artery in mice (12). In this study, NS-398 attenuated induction of caspase 3 during IH, blocked IH-induced PGE2 elevation, and attenuated the neurobehavioral deficits, strongly suggesting that COX-2 expression and activity are critical contributors to the adverse functional outcomes associated with episodic hypoxia during sleep. Of note, other COX-2 inhibitors, such as celecoxib and rofecoxib, are now routinely employed in clinical practice. In this study, we have established that NS398 crosses the blood-brain barrier, whereas it remains unclear whether other clinically used COX-2 inhibitors will do so. The mechanisms whereby COX-2 and its reaction product PGE2 contribute to IH-induced apoptosis remain to be defined (2, 45, 46). COX2 activity and downstream generation of prostanoids and Superoxide radicals are likely to be involved. In a recent study, Kondo and colleagues (47) suggested that prostaglandin D2 undergoes dehydration to yield bioactive cyclopentenone-type prostaglandins of the J2 series, such as 15-deoxy-Delta (12,14)-prostaglandin J2. They further showed that this compound induced apoptotic cell death in a neuroblastoma cell line through accumulation of p53 and activation of a death-inducing caspase cascade involving Fas and the Fas ligand (47). Thus, several prostanoids generated through COX-2 activation could directly induce neuronal cell death mechanisms (43). Alternatively, PGE2 could also enhance the induction of cytokines and thereby contribute to neurotoxicity (36, 48, 49) or could exacerbate neurotoxicity by facilitating astrocytic glutamate release (49). In fact, COX-2 inhibition by NS-398 protects neuronal cultures from glutamate neurotoxicity (31) and the damage produced by N-methyl-D-aspartate microinjection is attenuated in COX-2-null mice (11). It should be also stressed that COX-2 inhibition per se could lead to apoptosis in selected biologic substrates, possibly through alteration in mitochondrial calcium homeostasis (50). Although we did not find evidence for such occurrence in our rodent model, it is unclear whether long-term treatment with COX-2 inhibitors may lead to increased apoptosis in neural tissue.

In summary, we have shown that COX-2 plays a prominent role in the pathophysiologic mechanisms mediating spatial learning deficits associated with the episodic hypoxia of sleep-disordered breathing. These findings are consistent with the concept whereby IH triggers the initiation of an inflammatory cascade in vulnerable brain regions involving COX-2 increased expression and activity. It is therefore possible that COX-2 inhibitors may have potential therapeutic applications for the prevention of obstructive sleep apnea-associated neurobehavioral deficits."

#17 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 28 June 2009 - 10:29 AM

It looks like toning lax muscles by playing wind instruments or singing (or by other means) may help sleep apnea too...

http://www.talkabout...pic.php?t=13884
Alise (December 13, 2005):
"Hello, I am Alise Ojay, the person who created the 'Singing for Snorers' exercise programme mentioned by Charley. I've just read this discussion and would like to clear up a few misunderstandings.

I originally developed the 'Singing for Snorers' exercises purely for 'simple snorers' after the encouraging results of a pilot trial I ran with the University of Exeter in England, in 1999: Can Singing Exercises Reduce Snoring? A Pilot Study. Complement Ther Med 2000; 8(3); 151-156. An abstract of this pilot can be found at www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11068344&dopt=Abstract


Since its release, the 'Singing for Snorers' exercise programme has been tried both by simple snorers and people with sleep apnoea (UK spelling!) and it is in large part as a result of positive feedback from users in both categories that the current clinical randomized controlled trial is underway in the Otolaryngology (Ear, Nose & Throat) Department at the Royal Devon & Exeter Hospital in the UK. The aim of the trial is to determine whether in fact these singing exercises designed to tone the throat can be an effective treatment for snoring and mild to moderate sleep apnoea in some cases.

The trial started in June 2005 and is expected to take approximately 2 years. It will have two wings - 60 patients who are chronic simple snorers and 60 patients with mild to moderate sleep apnoea. Half the patients in each wing will sing the exercises for 3 months and half will have no intervention. It will take approximately 2 years to get the necessary number of patients through the trial.

'Singing for Snorers' is a 3 month programme. Once you know what you're doing the exercises take 12 minutes a day for the first month and 18 minutes a day for the second and third month. There are different sounds and tunes to focus movement in the soft palate, palatopharyngeal arch, tongue and nasopharynx.

I have always been clear that the exercises cannot work for everyone - 'Billinseattle' makes a valid point about anatomical obstructions - clearly as the action of the exercises is to tone lax muscles they can only help when lax muscles are a significant factor. Please see my website www.singingforsnorers.com for further details and the FAQ page where this very question is addressed."


1: BMJ. 2006 Feb 4;332(7536):266-70. Epub 2005 Dec 23. Links
Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial.

Puhan MA, Suarez A, Lo Cascio C, Zahn A, Heitz M, Braendli O.
Horten Centre, University of Zurich, 8091 Zurich, Switzerland.
OBJECTIVE: To assess the effects of didgeridoo playing on daytime sleepiness and other outcomes related to sleep by reducing collapsibility of the upper airways in patients with moderate obstructive sleep apnoea syndrome and snoring. DESIGN: Randomised controlled trial. SETTING: Private practice of a didgeridoo instructor and a single centre for sleep medicine. PARTICIPANTS: 25 patients aged > 18 years with an apnoea-hypopnoea index between 15 and 30 and who complained about snoring. INTERVENTIONS: Didgeridoo lessons and daily practice at home with standardised instruments for four months. Participants in the control group remained on the waiting list for lessons. MAIN OUTCOME MEASURE: Daytime sleepiness (Epworth scale from 0 (no daytime sleepiness) to 24), sleep quality (Pittsburgh quality of sleep index from 0 (excellent sleep quality) to 21), partner rating of sleep disturbance (visual analogue scale from 0 (not disturbed) to 10), apnoea-hypopnoea index, and health related quality of life (SF-36). RESULTS: Participants in the didgeridoo group practised an average of 5.9 days a week (SD 0.86) for 25.3 minutes (SD 3.4). Compared with the control group in the didgeridoo group daytime sleepiness (difference -3.0, 95% confidence interval -5.7 to -0.3, P = 0.03) and apnoea-hypopnoea index (difference -6.2, -12.3 to -0.1, P = 0.05) improved significantly and partners reported less sleep disturbance (difference -2.8, -4.7 to -0.9, P < 0.01). There was no effect on the quality of sleep (difference -0.7, -2.1 to 0.6, P = 0.27). The combined analysis of sleep related outcomes showed a moderate to large effect of didgeridoo playing (difference between summary z scores -0.78 SD units, -1.27 to -0.28, P < 0.01). Changes in health related quality of life did not differ between groups. CONCLUSION: Regular didgeridoo playing is an effective treatment alternative well accepted by patients with moderate obstructive sleep apnoea syndrome. Trial registration ISRCTN: 31571714.
PMID: 16377643 [PubMed - indexed for MEDLINE]


1: Sleep Med. 2009 Jun;10(6):657-60. Epub 2008 Nov 17. Links
Risk of sleep apnea in orchestra members.

Brown DL, Zahuranec DB, Majersik JJ, Wren PA, Gruis KL, Zupancic M, Lisabeth LD.
Stroke Program, University of Michigan Medical School, The Cardiovascular Center - Stroke Program, 1500 E. Medical Center Drive - SPC#5855, Ann Arbor, MI 48109-5855, USA. devinb@umich.edu
BACKGROUND: Obstructive sleep apnea (OSA) is a common condition with substantial health consequences. A recent randomized trial found that playing the didgeridoo improved both subjective and objective sleep measures. We undertook a cross-sectional survey of professional orchestra players to test the hypothesis that playing a wind instrument would be associated with a lower risk of OSA. METHODS: An anonymous internet-based survey of professional orchestra members assessed risk of sleep apnea using the Berlin questionnaire. Multivariable logistic regression was used to test the association between playing a wind instrument and having a high risk score on the Berlin questionnaire, both unadjusted and adjusted for age, body mass index, and gender. RESULTS: A total of 1,111 orchestra members responded, including 369 (33%) wind instrument players. Wind players were more often male and had a higher body mass index than non-wind players. Of all musicians, 348 (31%) had a high risk of sleep apnea. Wind players were more likely than non-wind players to be at high risk in unadjusted analysis (Odds ratio=1.47, 95% CI 1.13, 1.91), though this association was not significant in adjusted analysis (Odds ratio=1.12 (0.82, 1.54)). CONCLUSION: Playing a wind instrument was not associated with a lower risk of OSA.
PMID: 19014898 [PubMed - in process]


http://www.medpageto...rage/APSS/14647
APSS: Playing a Bassoon Protects Against Sleep Apnea

By Paula Moyer, Contributing Writer, MedPage Today
Published: June 10, 2009
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
Earn CME/CE credit
for reading medical news

SEATTLE, June 10 -- Compared with other members of an orchestra, musicians who played a high-resistance woodwind instrument were less likely to develop obstructive sleep apnea, researchers found. Action Points
Explain to interested patients that some musicians have less risk for sleep apnea than others.


Note that researchers don't know why those who play high-resistance woodwind instruments, such as bassoons, are so protected.


Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
In a study of 901 professional musicians, the woodwind players also had a lower risk of apnea than did singers or conductors, according to Christopher P. Ward, Ph.D., an assistant professor of psychiatry at the University of Houston-Clear Lake, who reported the findings at the meeting of the Associated Professional Sleep Societies here.

High-resistance woodwind instruments are those in the double-reed category, such as oboes, English horns, and bassoons.

The protective effect was only observed in those musicians who practiced an average of three hours a day, Dr. Ward said.

A musician himself -- he plays the trumpet and once served as interim band conductor at a college where he was teaching -- Dr. Ward said he did not know the exact mechanism that protects double-reed musicians.

Based on results of this study, Dr. Ward theorized that training sleep apnea patients to play double-reed instruments could be therapeutic.

However, Dr. Ward acknowledged that novices were unlikely to rapidly develop the needed embouchure -- the movement of facial muscles and placement of lip and tongue that allow music to be played on a wind instrument -- to sustain at least three hours of practice every day.

Dennis Nicholson, M.D., of the Sleep Disorders Center of Pomona Valley Hospital in Pomona, Calif., said it was possible that the embouchure specific to the double-reed instrument has characteristics that would help sleep apnea patients.

"This is a continuation of some previous literature that suggested that muscle training can improve sleep apnea, at least in some patients," said Dr. Nicholson, who was not involved in the study.

According to Dr. Nicholson, previous studies of musicians and obstructive sleep apnea revealed varying results among those who played wind instruments.

Dr. Nicholson suggested that a useful target for study would be identification of the specific muscle groups that are involved in playing a double-reed instrument so that patients could be trained in exercises using those muscles.

That, he said, would be a more practical application than attempting to teach patients to play double-reed instruments.

And, while Dr. Nicholson said he believes the finding deserves further study, he cautioned that the analysis was based on self-reported data as to practice time and apnea diagnosis.

Dr. Ward and colleagues followed 901 professional musicians. In the group overall, 41 (4.6%) reported an obstructive sleep apnea diagnosis and 29.2% were at high risk for it.

There was no statistically significant difference between instrumentalists, of whom 29.1% were at high risk, and noninstrumentalists -- conductors and singers -- of whom 33.3% were at high risk.

When the investigators analyzed the risk of apnea according to instrument type, the rate of high risk for those who played high-resistance woodwinds was significantly lower than it was for noninstrumentalists and for other instrumentalists (P=0.049).

Dr. Ward said that he received no outside funding for the study.
Both he and Dr. Nicholson said that they had no potentially conflicting financial ties to disclose.


Primary source: Associated Professional Sleep Societies Meeting
Source reference:
Ward CP, et al "Risk of obstructive sleep apnea in wind musicians" SLEEP 2009, 32: A233.


http://www.liptrainer.com/
Lip Trainer Patakara® designed to exercise Orbicular muscle


http://en.wikipedia....ris_oris_muscle
In human anatomy, the orbicularis oris muscle is the sphincter muscle around the mouth.
It is also one of the muscles used in the playing of all brass instruments and some woodwind instruments.
This muscle closes the mouth and puckers the lips when it contracts.

sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

#18 Jacovis

  • Topic Starter
  • Guest
  • 247 posts
  • 1

Posted 28 June 2009 - 11:11 AM

I have noticed a consistent effect since my Somnomed Mandibular Advancement Splint has been extended to 9 mm by the dentist. Basically I have smoother skin under the eyes in the morning and throughout the day even. I was resigned to having to live with bags under the eyes all my life (I just thought it was genetic) so that is great!
The 'increased smoothness of skin under the eyes' effect seems similar to what use to happen when I took strong antioxidant supplements over a period of many hours (for example Vitamin C, Grape Seed Extract, Green Tea, R-Lipoic Acid).
So I am thinking that the Somnomed MAS/sleeping on an angle combo has significantly reduced Oxidative Stress in my body (that arose from the mild sleep disordered breathing problem).

I have read that EEG arousals have been found to progressively increase from the younger to the older age groups (see studies below). And I assume this includes everyone and not just people with a diagnosed sleep disordered breathing problem. Therefore I wonder would it be an effective anti-ageing strategy for these 'normal, healthy' people to actually get quality Mandibular Advancement Splints and do other things to lessen arousals during sleep (such as eating less before bedtime, toning the relevant muscles or sleeping on an angle). In theory this might ramp down or at least maintain Oxidative Stress levels in the body.

Yes it might go against the medical practitioner's maxim of 'first do no harm' but following such an approach may be a more efficient way of doing things (rather than simply taking megadoses of antioxidants round the clock). Anyway such an approach would need to be tested first of course - perhaps they could see if cognitive decline levels might be reduced if 'normal, healthy' individuals being studied were following this approach.
I've learned myself that carefully throwing 'everything and the kitchen sink :)' at relatively mild health problems can lead to good results.

http://www.webscienc...cfm?ID=19979310
Age-related variations of EEG arousals in normal sleepers

BOSELLI M, PARRINO L, SPAGGIARI MC, SMERIERI A, DI GIOVANNI G, TERZANO MG.
Sleep Research 1997; 26: 5.
Sleep Disorders Center, Dept. of Neurology, University of Parrna, Italy

DISCUSSION
The progressive increase of EEG arousals from the younger to the older groups meets the well-established statement that aging is physiologically associated with sleep fragmentation.The significant positive correlation between age and the number of arousals per hour of sleep has been already described by Mathur and Douglas. In that study, however, sleep was recorded from both normal subjects and patients with sleep-related breathing disorders (snoring, apneas) and there was no acclimatization to or control of the environmental conditions in which the recordings were accomplished. In addition, the present study extends investigation to the relationship between Al and superficial sleep, deep sleep, NREM sleep and REM sleep. Overall, our data are in tune with recent findings of the Strasbourg's school on the phases d'activation transitoire (PAT), arousal patterns of sleep that share striking polygraphic similarities with the ASDA's arousals, and which are actually characterized by an age-related increase in TST [Total Sleep Time] and by an age-related stability in slow wave sleep and in REM sleep. In particular, the frequency of PAT occurring in REM sleep of young adults (13.8) is extremely close to our AI/REM in the same age group (13.3). With respect to NREM sleep, our study indicates that in this condition the EEG arousals lack any clearcut rhythmicity as they may be separated by mean intervals between 2 minutes (elderly) and 4 minutes (teenagers). In contrast, it has been ascertained that throughout all ages the arousal level oscillates in NREM sleep around a 20-40 second centered periodicity. A periodicity reflected by the cyclic alternating pattern (CAP), in which the ASDA's arousals represent only part of the EEG features and are mostly expressed by the A2 and A3 subtypes.


http://www.pubmedcen...i?artid=2564772
J Clin Sleep Med. 2007 April 15; 3(3): 271–274.
PMCID: PMC2564772
Copyright © 2007 American Academy of Sleep Medicine
EEG Arousal Norms by Age
Michael H. Bonnet, PhD and Donna L. Arand, PhD
Dayton Department of Veterans Affairs Medical Center, Wright State University, and Wallace Kettering Neuroscience Institute, Dayton, OH
Address correspondence to: Michael H. Bonnet, Ph.D. (151N), Dayton Department of Veterans Affairs Medical Center, 4100 W. Third Street, Dayton, OH 45428, Phone: (937) 267-3910, Fax: (937) 267-5317, Email: bonnetmichael@yahoo.com
Received August 2006; Accepted September 2006.

Abstract
Study Objectives:
Brief arousals have been systematically scored during sleep for more than 20 years. Despite significant knowledge concerning the importance of arousals for the sleep process in normal subjects and patients, comprehensive age norms have not been published.
Methods:
Seventy-six normal subjects (40 men) without sleep apnea or periodic limb movements of sleep, aged 18 to 70 years, slept in the sleep laboratory for 1 or more nights. Sleep and arousal data were scored by the same scorer for the first night (comparable to clinical polysomnograms) and summarized by age decade.
Results:
There were no statistically significant differences for sex or interaction of sex by age (p > .5 for both). The mean arousal index increased as a function of age. Newman-Keuls comparisons (.05) showed arousal index in the 18- to 20-year and 21- to 30-year age groups to be significantly less than the arousal index in the other 4 age groups. Arousal index in the 31-to 40-year and 41-to 50-year groups was significantly less than the arousal index in the older groups. The arousal index was significantly negatively correlated with total sleep time and all sleep stages (positive correlation with stage 1 and wake).
Conclusions:
Brief arousals are an integral component of the sleep process. They increase with other electroencephalographic markers as a function of age. They are highly correlated with traditional sleep-stage amounts and are related to major demographic variables. Age-related norms may make identification of pathologic arousal easier.
Citations:
Bonnet M; Arand D. EEG Arousal Norms by Age. J Clin Sleep Med 2007;3(3):271–274
Keywords: EEG arousal, arousal, ontogeny, sleep stages

Edited by Visionary7903, 28 June 2009 - 11:14 AM.





3 user(s) are reading this topic

0 members, 3 guests, 0 anonymous users